Stock OXB OXFORD BIOMEDICA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Oxford Biomedica plc

Equities

OXB

GB00BDFBVT43

Real-time Estimate Cboe Europe
Other stock markets
 03:58:43 2024-06-26 EDT 		5-day change 1st Jan Change
303.5 GBX +1.17% Intraday chart for Oxford Biomedica plc -2.32% +38.31%
06-25 ArcticZymes Technologies Nominates New Chair MT
06-18 EARNINGS AND TRADING: Cordel thrilled by Middle East contract win AN

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company appears highly valued given the size of its balance sheet.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
OXFORD BIOMEDICA PLC Stock Oxford Biomedica plc
+38.31% 400M
B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.45% 122B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.96% 116B
B+
ARGENX SE Stock argenx SE
+25.27% 27.03B
B
BIONTECH SE Stock BioNTech SE
-20.05% 20.36B
B+
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.28% 15.91B
B
GENMAB A/S Stock Genmab A/S
-15.85% 16.43B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.6B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.91% 14.94B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.52% 13.59B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. OXB Stock
  4. Ratings Oxford Biomedica plc